|
End-of-day quote
Palestine Exchange
29/10/2026
|
5-day change | 1st Jan Change | ||
| 3.450 USD | -1.15% |
|
+2.07% | +50.00% |
| 08-13 | Jerusalem Pharmaceuticals Co. Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| 06-30 | Jerusalem Pharmaceuticals Announces Board Changes | CI |
| Market Cap | 124M 111M 102M 92.71M 173M 11.79B 177M 1.22B 490M 6.2B 466M 456M 19.56B | P/E 2024 |
13.7x | P/E 2025 | 8.13x |
|---|---|---|---|---|---|
| Enterprise Value | 113M 101M 93.34M 84.57M 158M 10.76B 161M 1.11B 447M 5.66B 425M 416M 17.85B | EV / Sales 2024 |
1.47x | EV / Sales 2025 | 1.47x |
| Free-Float |
34.87% | Yield 2024 |
2.09% | Yield 2025 | 3.26% |
| 1 day | -1.15% | ||
| 1 week | +2.07% | ||
| 1 month | -2.27% | ||
| 3 months | -8.00% | ||
| 6 months | -9.45% | ||
| Current year | +50.00% |
| 1 week | 3.33 | 3.49 | |
| 1 month | 3.33 | 3.6 | |
| Current year | 2.28 | 4 | |
| 1 year | 2.01 | 4 | |
| 3 years | 1.74 | 4 | |
| 5 years | 1.36 | 4 | |
| 10 years | 0.8 | 4 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 30/06/2013 | |
Mohammed Natour
DFI | Director of Finance/CFO | - | 29/02/2020 |
Lina Masrouji
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/1988 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 91 | - | |
Nidal Kamal
BRD | Director/Board Member | - | - |
| Director/Board Member | - | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.15% | +2.07% | +72.50% | +84.99% | 124M | ||
| +3.19% | +11.31% | +64.28% | +155.91% | 1,263B | ||
| -0.73% | +3.56% | +44.65% | +84.17% | 658B | ||
| +1.41% | +3.24% | +35.25% | +108.88% | 521B | ||
| +0.42% | +3.20% | +55.81% | +72.50% | 391B | ||
| +2.18% | +2.93% | +73.90% | +45.59% | 369B | ||
| +1.12% | +4.52% | +34.76% | +58.24% | 307B | ||
| +6.96% | +8.86% | +11.95% | +36.20% | 290B | ||
| +1.15% | +6.09% | +56.15% | +82.25% | 252B | ||
| +3.06% | +9.38% | +42.48% | +117.32% | 212B | ||
| Average | +1.76% | +5.31% | +49.17% | +84.60% | 426.21B | |
| Weighted average by Cap. | +2.01% | +6.60% | +50.51% | +100.44% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 39.82M 35.66M 32.81M 29.72M 55.56M 3.78B 56.6M 391M 157M 1.99B 149M 146M 6.27B | 48.95M 43.84M 40.32M 36.53M 68.29M 4.65B 69.57M 481M 193M 2.44B 184M 180M 7.71B |
| Net income | 5.04M 4.51M 4.15M 3.76M 7.03M 478M 7.16M 49.49M 19.87M 252M 18.91M 18.5M 794M | 10.18M 9.12M 8.39M 7.6M 14.21M 967M 14.47M 100M 40.16M 509M 38.22M 37.4M 1.6B |
| Net Debt | -10.32M -9.24M -8.5M -7.7M -14.4M -980M -14.67M -101M -40.71M -516M -38.74M -37.91M -1.63B | -10.9M -9.76M -8.98M -8.13M -15.2M -1.03B -15.49M -107M -42.97M -544M -40.89M -40.02M -1.72B |
Employees
595
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/10/26 | US$3.450 | -1.15% | 1,109 |
| 27/10/26 | US$3.490 | +2.65% | 240 |
| 25/10/26 | US$3.400 | +0.59% | 9,200 |
- Stock Market
- Stocks
- JPH Stock
Select your edition
All financial news and data tailored to specific country editions
















